2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Pain
10
Neoplasms
9
Marijuana Abuse
5
Cancer Pain
5
Glioblastoma
2
Squamous Cell Carcinoma of Head and Neck
1
Signs and Symptoms
1
Recurrence
1
Parasomnias
1
Pancreatic Neoplasms
1
Neuralgia
1
Nausea
1
Multiple Sclerosis
1
Mouth Neoplasms
1
Marijuana Use
1
Diabetes Mellitus
1
Chronic Pain
1
Cachexia
1
Breast Neoplasms
1
Brain Neoplasms
1
Anxiety Disorders
1
Anorexia
1
Advanced Malignant Solid Tumor
1
Advanced Cancer
1
1- Cancer Patients During Chemotherapy Treatment
1
Interventions
Dexamethasone
38
Aprepitant
31
Ondansetron
27
Palonosetron
25
Granisetron
16
Calcium Dobesilate
15
Olanzapine
13
Therapeutics
8
dexamethasone acetate
7
Cyclophosphamide
7
fosaprepitant
6
casopitant
6
Doxorubicin
6
Radiotherapy
5
netupitant
4
dolasetron
4
dexamethasone 21-phosphate
4
Vincristine
4
Tropisetron
4
Metoclopramide
4
Acupressure
4
Yoga
3
Surveys and Questionnaires
3
Psychiatric Rehabilitation
3
Prochlorperazine
3
Lorazepam
3
Electroacupuncture
3
Dronabinol
3
Cisplatin
3
Analgesia
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Nausea
×
nabiximols
×
Clear all
NCT03948074
2025-09-10
CAFCARS
British Columbia Cancer Agency
Phase 2
Completed
91 enrolled